pharma news today obesity drugs glp-1 Roche was among the first pharmaceutical companies to research in the glucagon-like peptide-1 (GLP-1) class but abandoned the field after late-stage flops just before the latest boom began. Having Market Overview: GLP-1 Agonists and
Description
Imagine if you were a big drug company with shareholders, profits to lose, etc., and you just spent ~$1 billion and ~10 years to bring a drug to market
But Pfizer seems to have concluded that the toxicity question mark would damage its ability to compete in a relatively crowded space
We restock weekly to ensure that we have the best quality steroids when you want them
Nausea, vomiting and diarrhoea are some of the most common side effects
The Precision Peptide Genetic Test ($99) analyzes variants in GLP1R, GIPR, FTO, and MC4R that predict how you respond to appetite hormones and dopamine signaling
